Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2010-03-11
2011-11-22
Saeed, Kamal (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S719000, C514S729000, C558S423000, C568S633000, C568S719000
Reexamination Certificate
active
08063102
ABSTRACT:
The present invention relates to novel tetrahydronaphthalen-2-ol derivatives, to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular to their use for the manufacture of a medicament for the prevention or treatment of lower urinary tract symptoms, benign prostate hyperplasia, prostate cancer, hot flushes, anxiety, depression, breast cancer, medullary thyroid carcinoma, ovarian cancer, inflammatory bowel disease, arthritis, endometriosis, and colon cancer.
REFERENCES:
patent: 7531571 (2009-05-01), Veeneman et al.
patent: 7846966 (2010-12-01), Veeneman et al.
patent: 00200713.6 (2000-03-01), None
patent: WO01/64665 (2001-09-01), None
patent: WO03/044006 (2003-05-01), None
patent: WO2006/088716 (2006-08-01), None
Lala et al., Role of nitric oxide in tumor progression: Lessons from experimental tumors, Cancer and Metastasis Reviews (1998), 17, 91-106.
Golub et al., Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring, Science (1999), vol. 286, 531-537.
Chan, K, et al., “Estrogen Receptor Subtypes in Ovarian Cancer,” Obstetrics & Gynecology, Jan. 2008, vol. 111, No. 1, pp. 144-151.
Cheng, J., et al., “Expression of estrogen receptor β in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis,” FEBS Letters, 2004, vol. 566, pp. 169-172.
Cho, M. A., et al., “Expression and role of estrogen receptor α and β in medullary thyroid carcinoma: different roles in cancer growth and apoptosis,” Journal of Endocrinology, 2007, vol. 195, pp. 255-263.
Coleman, I. M., et al., “Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes”, Neoplasia, 2006, vol. 8, No. 10, pp. 862-878.
Ellem, S. J., et al., “Treating prostate cancer: A rationale for targeting local oestrogens,” Nature Reviews Cancer, 2007, vol. 7, No. 8, pp. 621-627.
Grady, D., et al., “MF101, a selective estrogen receptor β modulator for the treatment of menopausal hot flushes: a phase II clinical trial,” Menopause, 2009, vol. 16, No. 3, pp. 458-465.
Harris, H.A., et al., “Evaluation of an Estrogen Receptor-β Agonist in Animal Models of Human Disease,” Endocrinology, 2003, vol. 144, No. 10, pp. 4241-4249.
Harris, H. A., et al., “A selective estrogen receptor-β agonist causes lesion regression in an experimentally induced model of endometriosis,” Human Reproduction, 2005, vol. 20, No. 4, pp. 936-941.
Harris, H. A., “Estrogen Receptor-β: Recent Lessons from in Vivo Studies,” Molecular Endocrinology, 2007, vol. 21, No. 1, pp. 1-13.
Hartman, J., et al., “Estrogen Receptor β Inhibits Angiogenesis and Growth of T47D Breast Cancer Xenografts,” Cancer Research, Dec. 2006, vol. 66, No. 23, pp. 11207-11213.
Imamov, O., et al. “Estrogen receptor β regulates epithelial cellular differentiation in the mouse ventral prostate,” PNAS, 2004, vol. 101, No. 25, pp. 9375-9380.
Lazennec, G., “Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis,” Cancer Letters, 2006, vol. 231, pp. 151-157.
Leav, I., et al., “Comparative Studies of the Estrogen Receptors β and α and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastic Carcinoma,” American Journal of Pathology, 2001, vol. 159, No. 1, pp. 79-92.
Opas, E. E., et al., “Estrogenic control of thermoregulation in ERαKO and ERβKO mice,” Maturitas, 2006, vol. 53, pp. 210-216.
Risbridger, G. P., et al., “Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling,” Journal of Molecular Endocrinology, 2007, vol. 39, pp. 183-188.
Stella, V. J., et al., “Prodrug strategies to overcome poor water solubility,” Advanced Drug Delivery Reviews, 2007, vol. 59, pp. 677-694.
Ullrich, J. W., et al., “Estrogen receptor modulator review,” Expert Opinion on Therapeutic Patents, 2006, vol. 16, No. 5, pp. 559-572.
Wada-Hiraike, O., et al., “New developments in oestrogen signalling in colonic epithelium”, Biochemistry Society Transactions, 2006, vol. 34, Part 6, pp. 1114-1116.
Walf, A. A., et al., “Antidepressant effects of ERβ-selective estrogen receptor modulators in the forced swim test,” Pharmacology, Biochemistry and Behavior, 2004, vol. 78, pp. 523-529.
Walf, A. A., et al., “Erβ-Selective Estrogen Receptor Modulators Produce Antianxiety Behavior and Administered Systemically to Ovariectomized Rats,” Neuropsychopharmacology, 2005, vol. 30, pp. 1598-1609.
Written Opinion issued by the International Searching Authority in connection with PCT International Application No. PCT/EP2010/053167, filed Mar. 12, 2010.
Stock Herman Thijs
Teerhuis Neeltje Miranda
Veeneman Gerrit Herman
Bianchi Kristin
Camara Valerie J.
Marucci Maria V.
N.V. Organon
Saeed Kamal
LandOfFree
Tetrahydronaphthalen-2-ol derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydronaphthalen-2-ol derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydronaphthalen-2-ol derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4263733